| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2017 ( Subtotal = -$300,055 ) |
| | 2017 | 2012 | LENTIGEN CORPORATION | 910 CLOPPER RD STE 200 SOUTH BUILDING | GAITHERSBURG | MD | 20878-1361 | MONTGOMERY | USA | R44CA126461 | Clinical Vector for TCR Immunotherapy Targeted to Melanoma | 000 | 4 | NIH | 9/30/2017 | -$300,055 |
|
| Issue Date FY: 2015 ( Subtotal = $0 ) |
| | 2015 | 2011 | LENTIGEN CORPORATION | 910 CLOPPER ROAD SUITE 200S | GAITHERSBURG | MD | 20878 | MONTGOMERY | USA | R42CA128269 | Lentiviral-MGMT gene transfer into hematopoietic stem cells | 000 | 2 | NIH | 10/24/2014 | $0 |
|
| Issue Date FY: 2014 ( Subtotal = $0 ) |
| | 2014 | 2012 | LENTIGEN CORPORATION | 910 CLOPPER ROAD SUITE 200S | GAITHERSBURG | MD | 20878 | MONTGOMERY | USA | R44CA126461 | Clinical Vector for TCR Immunotherapy Targeted to Melanoma | 000 | 4 | NIH | 9/9/2014 | $0 |
| | 2014 | 2011 | LENTIGEN CORPORATION | 910 CLOPPER ROAD SUITE 200S | GAITHERSBURG | MD | 20878 | MONTGOMERY | USA | R42CA128269 | Lentiviral-MGMT gene transfer into hematopoietic stem cells | 000 | 2 | NIH | 3/7/2014 | $0 |
|
| Issue Date FY: 2012 ( Subtotal = $1,729,819 ) |
| | 2012 | 2012 | LENTIGEN CORPORATION | 1450 SOUTH ROLLING ROAD | BALTIMORE | MD | 21227-3869 | BALTIMORE | USA | R44CA126461 | Clinical Vector for TCR Immunotherapy Targeted to Melanoma | 000 | 4 | NIH | 9/5/2012 | $1,729,819 |
| | 2012 | 2010 | LENTIGEN CORPORATION | 910 CLOPPER ROAD SUITE 200S | GAITHERSBURG | MD | 20878 | MONTGOMERY | USA | R41DK085944 | LENTIVIRAL GENE THERAPY FOR MUCOPOLYSACCHARIDOSIS | 000 | 1 | NIH | 3/9/2012 | $0 |
|
| Issue Date FY: 2011 ( Subtotal = $4,311,350 ) |
| | 2011 | 2011 | LENTIGEN CORPORATION | 1450 SOUTH ROLLING ROAD | BALTIMORE | MD | 21227-3869 | BALTIMORE | USA | R42CA128269 | Lentiviral-MGMT gene transfer into hematopoietic stem cells | 000 | 2 | NIH | 8/31/2011 | $2,150,576 |
| | 2011 | 2011 | LENTIGEN CORPORATION | 1450 SOUTH ROLLING ROAD | BALTIMORE | MD | 21227-3869 | BALTIMORE | USA | R44CA126461 | Clinical Vector for TCR Immunotherapy Targeted to Melanoma | 000 | 3 | NIH | 7/1/2011 | $2,160,774 |
|
| Issue Date FY: 2010 ( Subtotal = $2,058,725 ) |
| | 2010 | 2010 | LENTIGEN CORPORATION | 1450 SOUTH ROLLING ROAD | BALTIMORE | MD | 21227-3869 | BALTIMORE | USA | R42CA128269 | Lentiviral-MGMT gene transfer into hematopoietic stem cells | 000 | 1 | NIH | 9/30/2010 | $502,085 |
| | 2010 | 2010 | LENTIGEN CORPORATION | 1450 SOUTH ROLLING ROAD | BALTIMORE | MD | 21227-3869 | BALTIMORE | USA | R44CA126461 | Clinical Vector for TCR Immunotherapy Targeted to Melanoma | 000 | 2 | NIH | 6/16/2010 | $1,191,796 |
| | 2010 | 2010 | LENTIGEN CORPORATION | 1450 SOUTH ROLLING ROAD | BALTIMORE | MD | 21227-3869 | BALTIMORE | USA | R41DK085944 | LENTIVIRAL GENE THERAPY FOR MUCOPOLYSACCHARIDOSIS | 000 | 1 | NIH | 3/3/2010 | $364,844 |
|
| Issue Date FY: 2009 ( Subtotal = $423,638 ) |
| | 2009 | 2009 | LENTIGEN CORPORATION | 1450 SOUTH ROLLING ROAD | BALTIMORE | MD | 21227-3869 | BALTIMORE | USA | R43CA141738 | UNIVERSAL MUC1 TARGETED IMMUNOTHERAPY | 000 | 1 | NIH | 8/28/2009 | $140,720 |
| | 2009 | 2009 | LENTIGEN CORPORATION | 1450 SOUTH ROLLING ROAD | BALTIMORE | MD | 21227-3869 | BALTIMORE | USA | R43AI084310 | A NOVEL METHOD OF GENERATING HEPATITIS C VIRUS-LIKE PARTICLES USING LENTIVIRUS | 000 | 1 | NIH | 8/26/2009 | $282,918 |
| | 2009 | 2009 | LENTIGEN CORPORATION | 910 CLOPPER ROAD SUITE 200S | GAITHERSBURG | MD | 20878 | MONTGOMERY | USA | R43AI084310 | A NOVEL METHOD OF GENERATING HEPATITIS C VIRUS-LIKE PARTICLES USING LENTIVIRUS | 001 | 1 | NIH | 9/3/2009 | $0 |
| | 2009 | 2008 | LENTIGEN CORPORATION | 910 CLOPPER ROAD SUITE 200S | GAITHERSBURG | MD | 20878 | MONTGOMERY | USA | R43AR054291 | LENTIVIRAL EXPRESSED GROWTH FACTORS AS A NOVEL THERAPY IN WOUND HEALING | 000 | 1 | NIH | 7/3/2009 | $0 |
| | 2009 | 2006 | LENTIGEN CORPORATION | 910 CLOPPER ROAD SUITE 200S | GAITHERSBURG | MD | 20878 | MONTGOMERY | USA | R41AI071927 | SUICIDE OF HIV-INFECTED CELLS BY TAT-INDUCIBLE SHRNA | 001 | 1 | NIH | 8/28/2009 | $0 |
| | 2009 | 2006 | LENTIGEN CORPORATION | 910 CLOPPER ROAD SUITE 200S | GAITHERSBURG | MD | 20878 | MONTGOMERY | USA | R41AI071927 | SUICIDE OF HIV-INFECTED CELLS BY TAT-INDUCIBLE SHRNA | 000 | 1 | NIH | 10/22/2008 | $0 |
|
| Issue Date FY: 2008 ( Subtotal = $119,144 ) |
| | 2008 | 2008 | LENTIGEN CORPORATION | 1450 SOUTH ROLLING ROAD | BALTIMORE | MD | 21227 | BALTIMORE | USA | R43AR054291 | LENTIVIRAL EXPRESSED GROWTH FACTORS AS A NOVEL THERAPY IN WOUND HEALING | 000 | 1 | NIH | 9/11/2008 | $119,144 |
|
| Issue Date FY: 2006 ( Subtotal = $264,329 ) |
| | 2006 | 2006 | LENTIGEN CORPORATION | 1450 SOUTH ROLLING ROAD | BALTIMORE | MD | 21227 | BALTIMORE | USA | R41AI071927 | SUICIDE OF HIV-INFECTED CELLS BY TAT-INDUCIBLE SHRNA | 000 | 1 | NIH | 8/4/2006 | $264,329 |
|
|
